Cavan John T 4
4 · ContraVir Pharmaceuticals, Inc. · Filed Jul 3, 2018
Insider Transaction Report
Form 4
Cavan John T
Chief Financial Officer
Transactions
- Purchase
Series C Convertible Preferred Stock
2018-07-03$1000.00/sh+15$15,000→ 15 totalExercise: $1.55From: 2018-07-03→ Common Stock (9,678 underlying) - Purchase
Warrants
2018-07-03$1000.00/sh+8,625$8,625,000→ 8,625 totalExercise: $1.55From: 2018-07-03Exp: 2023-07-03→ Common Stock (8,625 underlying)
Footnotes (3)
- [F1]Each share of Series C Convertible Preferred Stock is convertible into the number of shares of Common Stock equal to the stated value of $1,000 divided by $1.55.
- [F2]Shares of Series C Convertible Preferred Stock do not expire.
- [F3]Shares of Series C Convertible Preferred Stock and Warrants were issued as part of a unit, with each unit consisting of one share of Series C Convertible Preferred Stock and 575 Warrants